| First Author | Salloukh HF | Year | 2000 |
| Journal | Oncogene | Volume | 19 |
| Issue | 38 | Pages | 4362-74 |
| PubMed ID | 10980612 | Mgi Jnum | J:64601 |
| Mgi Id | MGI:1889693 | Doi | 10.1038/sj.onc.1203804 |
| Citation | Salloukh HF, et al. (2000) Early events in leukemogenesis in P190Bcr-abl transgenic mice. Oncogene 19(38):4362-74 |
| abstractText | The activated tyrosine kinase, Bcr-abl, is implicated in a number of hematopoietic malignancies. The exact biological mechanism by which the kinases transforms cells is still not well delineated. Previous data has suggested that the inhibition of apoptosis and the deregulation of cell cycle progression as the result of P210Bcr-abl expression might contribute to leukemogenesis. In vitro systems in which Bcr-Abl is over-expressed have concluded that similar growth regulatory pathways are affected as a result of the expression of both P210 and P190Bcr-abl. Here, we utilized an in vitro P190Bcr-abl leukemia mouse model to dissect the early events that contribute to transformation by this isoform of Bcr-Abl. In this mouse model P190Bcr-abl is expressed as a low but physiologically relevant level in that all mice develop pre-B leukemia lymphomas. We show that cell cycle and apoptotic responses to DNA damage are intact in bone marrow and spleen cells of such animals. We also demonstrate a normal induction of p21WAF-1/CIP1 in both hematopoietic and non-hematopoietic tissue as a result of genotoxic stress. We suggest that P190Bcr-abl induced transformation is different than that of P210Bcr-abl. Oncogene (2000) 19, 4362 - 4374 |
